This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
This document describes how to strengthen surveillance in hospital settings for the identification of severely affected patients infected with avian influenza virus in the EU/EEA.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
Version 6.1 is the final protocol for the third EU-wide point prevalence survey in acute care hospitals (PPS 2022–2023). It contains important changes compared to protocol version 5.3 (PPS 2016–2017), including on healthcare-associated COVID-19.
This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.